(AVCJ by Justin Niessner) – Hong Kong’s Immuno Cure BioTech, a vaccine and antibodies developer focused on cancers, inflammatory and infectious diseases, has raised USD 27m in Series A funding featuring Gobi Partners.
It comes with confirmation of a USD 12m tranche featuring Alibaba Hong Kong Entrepreneurs Fund’s AEF Greater Bay Area Fund, which is managed by Gobi. Established in 2016, Gobi’s GBA unit is the sole GP of both Alibaba Hong Kong Entrepreneurs Fund and the AEF Greater Bay Area Fund.
Immuno Cure has two DNA vaccine candidates currently in clinical trials. They include ICVAX, a HIV/AIDS candidate in phase-one trials in Shenzhen, and ICCOV, a preventive COVID-19 booster vaccine candidate, in phase-two trials in Hong Kong. The fresh capital will be used to advance product development and prepare for a Hong Kong IPO.
To be used for the internal business of the assigned users only. Sharing, distributing or forwarding the entirety or any part of this article in any form to anyone that does not have access under your agreement is strictly prohibited and doing so violates your contract and is considered a breach of copyright. Any unauthorized recipient or distributor of this article is liable to AVCJ for unauthorized use and copyright breach.
